Last reviewed · How we verify

Reslizumab IV

Teva Branded Pharmaceutical Products R&D, Inc. · Phase 1 active Small molecule

Reslizumab IV is a Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc.. It is currently in Phase 1 development.

At a glance

Generic nameReslizumab IV
SponsorTeva Branded Pharmaceutical Products R&D, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Reslizumab IV

What is Reslizumab IV?

Reslizumab IV is a Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc..

Who makes Reslizumab IV?

Reslizumab IV is developed by Teva Branded Pharmaceutical Products R&D, Inc. (see full Teva Branded Pharmaceutical Products R&D, Inc. pipeline at /company/teva-branded-pharmaceutical-products-r-d-inc).

What development phase is Reslizumab IV in?

Reslizumab IV is in Phase 1.

Related